Salud financiera de hoja de balance de eFFECTOR Therapeutics

Salud financiera controles de criterios 5/6

eFFECTOR Therapeutics tiene un patrimonio de los accionistas total de $-5.8M y una deuda total de $20.5M, lo que sitúa su ratio deuda-patrimonio en -353.5%. Sus activos y pasivos totales son $20.5M y $26.3M respectivamente.

Información clave

2,420.3%

Ratio deuda-patrimonio

US$20.02m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$25.38m
Patrimonio	US$827.00k
Total pasivo	US$26.30m
Activos totales	US$27.13m

Actualizaciones recientes sobre salud financiera

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($26.3M) de EFTR superan a sus pasivos a corto plazo ($25.6M).

Pasivo a largo plazo: Los activos a corto plazo de EFTR ($26.3M) superan a sus pasivos a largo plazo ($735.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: EFTR tiene más efectivo que su deuda total.

Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de EFTR se ha reducido en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: EFTR tiene suficiente cash runway para 7 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que EFTR disponga de suficiente cash runway para 7 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de eFFECTOR Therapeutics

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

Recent updates

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Price target decreased by 92% to US$22.50

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

Price target increased by 90% to US$275

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

Price target decreased by 11% to US$6.58

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Price target increased by 17% to US$7.38

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

Price target increased by 16% to US$6.33

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Price target decreased to US$8.60

Price target increased to US$10.75

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

Consensus forecasts updated

Price target decreased to US$10.68

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Consensus forecasts updated

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold US$475k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold US$407k worth of stock

Independent Director recently sold US$222k worth of stock

Independent Director recently sold US$917k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

eFFECTOR: Developing New Class Of Cancer Therapies

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera